A mesothelioma article was recently published in the scientific journal Lung Cancer that examines the benefits and costs of combination of Cisplatin and Pemetrexed with Carboplatin and Pemetrexed for mesothelioma chemotherapy.
Cystplatin and Pemetrexed combination chemotherapy is one of several chemotherapy options that have proven successful enough to treat patients with malignant pleural mesothelioma (MPM) mesothelioma, but this combination can be highly toxic to the body. There is no treatment and treatment for malignant mesothelioma cancer without any undesirable side effects.
In the journal the authors note that 'two random phases of the study in phase III show a benefit for the prognosis of mesothelioma with the use of antifolates such as raltitrexed or Pemetrexed, when combined with Cisplatin. The study has shown an absolute increase in overall survival averaging 2.6 and 2.8 months, compared with single treatment for Cisplatin. This has led many institutions to use Cisplatin and Pemetrexed as standard of palliative chemotherapy treatment for malignant pleural mesothelioma. '
Unfortunately, the combination of Cisplatin and Pemetrexed produces unwanted toxic effects and this prompted researchers to study other chemotherapy drugs to be combined with Pemetrexed. The researchers said, 'Recently, two phase II trials have been evaluated for the efficacy of Carboplatin and Pemetrexed in MPM. Both studies showed an overall response rate of 18.6 and 25%, with an average survival rate of 12.7 and 14 months. As a result of this result, we have performed a retrospective analysis of MPM patients treated with Carboplatin and Pemetrexed at our institution. '
In an attempt to find a combination of mesothelioma chemotherapy with little toxicity and side effects, the researchers investigated further by replacing Cisplatin with Carboplatin when paired with Pemetrexed. Using a retrospective approach, researchers evaluated 49 cases of malignant pleural mesothelioma given a combination of Carboplatin and Pemetrexed and compared the results with data combining Cisplatin chemotherapy with Pemetrexed.
The degree of disease control (known in the absence of a progressive mesothelioma via CT scan) for the patient was 69 percent, and the partial response and the percentage of disease stability by 28 percent and 41 percent. The clinical increase shown in the figure was 69 percent, the majority of patients reporting an increase in profits after two cycles of chemotherapy. Toxicity is generally low and better than Cisplatin toxicity with Pemetrexed.
The median time of treatment failure was 4.6 months. The mean overall survival in this study was 14 months, which compared with Cisplatin-pemetrexed for 12.1 months. The researchers point out, 'In conclusion, our data show a combination of Carboplatin and Pemetrexed may be an option in the treatment of mesothelioma, especially in patients with problems with the use of Cisplatin.'
Cystplatin and Pemetrexed combination chemotherapy is one of several chemotherapy options that have proven successful enough to treat patients with malignant pleural mesothelioma (MPM) mesothelioma, but this combination can be highly toxic to the body. There is no treatment and treatment for malignant mesothelioma cancer without any undesirable side effects.
In the journal the authors note that 'two random phases of the study in phase III show a benefit for the prognosis of mesothelioma with the use of antifolates such as raltitrexed or Pemetrexed, when combined with Cisplatin. The study has shown an absolute increase in overall survival averaging 2.6 and 2.8 months, compared with single treatment for Cisplatin. This has led many institutions to use Cisplatin and Pemetrexed as standard of palliative chemotherapy treatment for malignant pleural mesothelioma. '
Unfortunately, the combination of Cisplatin and Pemetrexed produces unwanted toxic effects and this prompted researchers to study other chemotherapy drugs to be combined with Pemetrexed. The researchers said, 'Recently, two phase II trials have been evaluated for the efficacy of Carboplatin and Pemetrexed in MPM. Both studies showed an overall response rate of 18.6 and 25%, with an average survival rate of 12.7 and 14 months. As a result of this result, we have performed a retrospective analysis of MPM patients treated with Carboplatin and Pemetrexed at our institution. '
In an attempt to find a combination of mesothelioma chemotherapy with little toxicity and side effects, the researchers investigated further by replacing Cisplatin with Carboplatin when paired with Pemetrexed. Using a retrospective approach, researchers evaluated 49 cases of malignant pleural mesothelioma given a combination of Carboplatin and Pemetrexed and compared the results with data combining Cisplatin chemotherapy with Pemetrexed.
The degree of disease control (known in the absence of a progressive mesothelioma via CT scan) for the patient was 69 percent, and the partial response and the percentage of disease stability by 28 percent and 41 percent. The clinical increase shown in the figure was 69 percent, the majority of patients reporting an increase in profits after two cycles of chemotherapy. Toxicity is generally low and better than Cisplatin toxicity with Pemetrexed.
The median time of treatment failure was 4.6 months. The mean overall survival in this study was 14 months, which compared with Cisplatin-pemetrexed for 12.1 months. The researchers point out, 'In conclusion, our data show a combination of Carboplatin and Pemetrexed may be an option in the treatment of mesothelioma, especially in patients with problems with the use of Cisplatin.'
EmoticonEmoticon